Xanthus Life Sciences' Symadex(TM) Shows Remyelination In Multiple
Sclerosis Animal Model

CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Xanthus Life Sciences, Inc.,
today announced that data from a study conducted with a Multiple
Sclerosis (MS) animal model demonstrated that Symadex(TM) permitted
remyelination by prevention of inflammatory cell infiltration. Stephen
J. Karlik, Ph.D., Professor of Diagnostic Radiology at the University
of Western Ontario, London, Ontario presented the research findings on
February 10, 2006 at the International Workshop on Myelin Imaging, in
Vancouver.

Dr. Karlik is widely recognized for investigating potential new
therapies for MS in a specialized animal model of human MS that
incorporates both inflammatory and demyelinating properties. Symadex
was found to produce remyelination in the study even after 40 days of
inflammatory insult by preventing the infiltration of autoreactive
cells into the central nervous system. Treatment proved to be effective
in both the acute and chronic presentations of disease.

"The early results from this study showed that the animals in the
study, which were paralyzed due to neurological impairment, were able
to recover and regain their mobility after treatment with Symadex,"
commented Dr. Karlik.

"Symadex is now in Phase 2 trials in oncology and the positive results
of this animal model study show the candidate's potential for treating
MS and provide the support needed to advance Symadex towards human
trials for MS," said Michael A. Boss, PhD. Chief Business Officer at
Xanthus.

About Symadex(TM)

Symadex (formerly C-1311) is a next-generation investigational drug
that has shown a potentially novel, targeted mechanism of action in
studies of cancer and autoimmune disease. Symadex was developed to
deliver efficacy comparable to the anthracenediones (e.g.,
Novantrone(R) (mitoxantrone)), but with a molecular scaffold intended
to reduce the cardio- and hemato-toxicities known to be associated with
these active drugs. Additionally, in previous preclinical studies,
Symadex has shown early evidence of both oral activity and efficacy in
various models of acquired drug resistance and autoimmune disease. The
Company is conducting Phase 2 clinical trials with Symadex in several
tumor indications and is also exploring the use of Symadex for the
treatment of a number of autoimmune diseases, such as Multiple
Sclerosis.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, unpredictable disease of the
central nervous system that, according to the National MS Society,
affects approximately 400,000 people in the United States and
approximately 2.5 million people worldwide. It is a disease typically
of young adults, mostly women, with onset typically between 20 and 50
years of age. Each hour someone is newly diagnosed. MS symptoms may
include vision problems, loss of balance, numbness, difficulty walking
and even complete paralysis.

About Xanthus Life Sciences, Inc.

Xanthus Life Sciences, Inc. is developing a portfolio of novel,
clinical- stage, small-molecule oncology drugs through a management
team whose accomplished track record encompasses all aspects of drug
development, from discovery through regulatory approval and
commercialization. The Company is applying its expertise both to
advance its current pipeline and expand it into indications of unmet
medical need beyond oncology.

Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
www.xanthus.com.

This press release contains forward-looking statements concerning
Xanthus that involve a number of risks and uncertainties. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words, "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may,"
and similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could cause
Xanthus' actual results to differ materially from those indicated by
such forward-looking statements, including risks as to whether results
obtained in early clinical studies or in preclinical studies such as
the studies referred to above will be indicative of results obtained in
future clinical trials or warrant additional trials; whether products
based on Xanthus' technology will advance through the clinical trial
process and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether the
company will have the cash resources to develop and commercialize its
products; and whether the patent and patent applications owned or
licensed by Xanthus will protect the Company's technology and prevent
others from infringing it. Xanthus disclaims any intention or
obligation to update any forward-looking statements.

Contacts: Kari Watson, MacDougall Biomedical Communications, Inc. -
kwatson@macbiocom.com or (508) 647-0209 John A. McCarthy, Jr., Senior
Vice President & CFO, Xanthus Life Sciences, Inc. -
john.mccarthy@xanthus.com or (617) 225-0522, x 125

Xanthus Life Sciences, Inc.
CONTACT: Kari Watson, MacDougall Biomedical Communications,
Inc.,508-647-0209, or kwatson@macbiocom.com; or John A. McCarthy, Jr.,
SeniorVice President & CFO, Xanthus Life Sciences, Inc. 617-225-0522,
ext. 125,or john.mccarthy@xanthus.com

Web site: http://www.xanthus.com/

(See Story from BioSpace.com) (02/13/2006)

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com

Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore

DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking